bluebird unveils $2.8m price for gene therapy Zynteglo on FDA approval
beta thalassaemia, bluebird bio, fda, gene therapy, regulatory approval, Zynteglo
0 Comment
bluebird bio
Second unanimous FDA adcomm vote boosts bluebird bio
beta thalassaemia, bluebird bio, fda, gene therapy, rare disease, regulatory
0 Comment
FDA panel backs bluebird’s CALD gene therapy, despite safety worries
bluebird bio, CALD, fda, gene therapy, rare disease, regulatory
0 Comment
ICER says bluebird bio’s $2.1m gene therapy is cost-effective
beta thalassaemia, bluebird bio, gene therapy, HEOR, ICER
0 Comment
Gene therapy specialist bluebird exits “untenable” European market
bluebird bio, Europe, gene therapy, pricing, rare disease, reimbursement
0 Comment
Bluebird claims EU nod for rare disease therapy Skysona
bluebird bio, CALD, EU, gene therapy, rare disease, regulatory approval
0 Comment
